In October 2008, the European Medicines Agency recommended the suspension of Acomplia after the Committee for Medicinal Products for Human Use (CHMP) had determined that the risks of Acomplia outweighed its benefits due to the risk of serious psychiatric problems, including suicide.  In November 2008 an advisory committee in Brazil recommended suspension as well, and that month Sanofi-Aventis suspended sale of the drug worldwide.  The EMA approval was withdrawn in January 2009.   In 2009 India prohibited the manufacture and sale of the drug. 
The typical profile for somebody who may benefit the most from nat mur is that of a very sensitive and refined individual. They may be very set in their ways and therefore aren’t always open to an outside perspective. They may feel insulted or easily wounded by the opinions or potential insults of others around them. They tend to be rather impatient people overall and can therefore come across as abrupt in nature. These are typically very serious people and can tend to be quite moody throughout the course of a typical day. Though they like the company of others, they tend to impose loneliness upon themselves.